Clinical TrialAug 6, 2026, 07:01 AM
Cartesian Therapeutics Advances Trials, Extends Runway to 2028
AI Summary
Cartesian Therapeutics provided an update on its clinical pipeline, announcing that Phase 3 AURORA trial data for Descartes-08 in myasthenia gravis (MG) is expected in 1Q27, with a BLA filing planned for mid-2027. The company also secured a strategic partnership with WestGene BioPharma to develop an in vivo CAR-T platform, with a Phase 1 trial expected to initiate in 2H26. Financially, Cartesian extended its cash runway into 2028 with $149.3 million in cash and up to $150 million in non-dilutive financing, supporting ongoing operations and precommercial readiness.
Key Highlights
- Phase 3 AURORA trial data for Descartes-08 in MG expected in 1Q27.
- Biologics License Application (BLA) filing for Descartes-08 in MG planned for mid-2027.
- New strategic licensing agreement with WestGene for in vivo CAR-T platform.
- Phase 1 in vivo trial with WestGene to initiate in 2H26, with data expected in 1H27.
- Cash, cash equivalents, and restricted cash totaled $149.3 million as of June 30, 2026.
- Cash runway extended into 2028 with up to $150 million non-dilutive financing.
- Q2 2026 R&D expenses increased to $20.4 million from $14.9 million YoY.
- Q2 2026 net income was $15.8 million, or $0.47 per basic share.
Price Impact
More from RNAC